Interleukin IL-17A inhibitor (Amgen)

N/A

Report date: 2025/03/20 15:31:59

NME

Base Information

Drug NameInterleukin IL-17A inhibitor (Amgen)

Drug Alias NameInterleukin IL-17A inhibitor (Nuevolution)small molecule cytokine x inhibitor (Nuevolution)Cytokine Xsmall molecule cytokine A inhibitor (Nuevolution)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionInterleukin 17A inhibitorsCytokine receptors antagonists

TargetsCytokine receptorsInterleukin 17A

Therapy Area/IndicationsInflammationPsoriasisArthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesDenmark

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNuevolution AS

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesNuevolution AS

Active IndicationsInflammationPsoriasisArthritis

Inactive IndicationsN/A

Other Information

ATC CodeN/A